Atlas Trials

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT07138209 · RECRUITING

Trial details

NCT number
NCT07138209
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed or Refractory Multiple Myeloma
Start date
2025-11-07
Primary completion
2027-12-01
Enrollment
228

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.